Erioflorin

Erioflorin acetate (5.6-55.5 μM; 24 h) inhibits parasite viability, increases autophagosomes, disrupts reservosomes, induces cytoplasmic vacuolization, reduces mitochondrial membrane potential, and enhances reactive oxygen species production in epimastigotes and trypomastigotes of Trypanosoma cruzi^[1].
Erioflorin (6-200 μM; 48 h) increases cell membrane permeability and induces cell death in DU-145 and 22Rv1 prostate cancer cells^[2].
Erioflorin (1.56-25 μM; 14 days) inhibits colony formation in DU-145 and 22Rv1 cells, with IC₅₀ values of 14.51 μM and 11.24 μM, respectively^[2].
Erioflorin (5-50 μM; 1-24 h) induces early and late apoptosis, increases reactive oxygen species levels, triggers mitochondrial membrane potential depolarization, upregulates the BAX/BCL-2 ratio, dose-dependently inhibits LPS (HY-D1056)-induced IκBα phosphorylation, and blocks the NF-κB pathway in DU-145 and 22Rv1 cells^[2].

Erioflorin (2.5-5 μM; 6 h-6 days) inhibits cell proliferation, increases the proportions of cells in the G2-M phase and sub-G1 phase, and suppresses cell migration in MCF7, HeLa and RKO cells^[3].
Erioflorin (0.0625-10 μM; 8-16 h) exerts a protein-stabilizing effect in HEK293 cells by preventing Pdcd4 from TPA (HY-18739)-induced degradation, blocks the binding of Pdcd4 to β-TrCP1, reduces its ubiquitination, and inhibits TPA-induced AP-1 and TNFα (HY-P704246)-induced NF-κB transcriptional activity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.